417 related articles for article (PubMed ID: 23418312)
1. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives.
Dieci MV; Arnedos M; Andre F; Soria JC
Cancer Discov; 2013 Mar; 3(3):264-79. PubMed ID: 23418312
[TBL] [Abstract][Full Text] [Related]
2. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.
Ronca R; Giacomini A; Rusnati M; Presta M
Expert Opin Ther Targets; 2015; 19(10):1361-77. PubMed ID: 26125971
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer.
Brooks AN; Kilgour E; Smith PD
Clin Cancer Res; 2012 Apr; 18(7):1855-62. PubMed ID: 22388515
[TBL] [Abstract][Full Text] [Related]
4. Targeting FGFR Signaling in Cancer.
Touat M; Ileana E; Postel-Vinay S; André F; Soria JC
Clin Cancer Res; 2015 Jun; 21(12):2684-94. PubMed ID: 26078430
[TBL] [Abstract][Full Text] [Related]
5. Targeting the fibroblast growth factor receptor family in cancer.
Hallinan N; Finn S; Cuffe S; Rafee S; O'Byrne K; Gately K
Cancer Treat Rev; 2016 May; 46():51-62. PubMed ID: 27109926
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors.
Hierro C; Rodon J; Tabernero J
Semin Oncol; 2015 Dec; 42(6):801-19. PubMed ID: 26615127
[TBL] [Abstract][Full Text] [Related]
7. Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma.
Cheng AL; Shen YC; Zhu AX
Oncology; 2011; 81(5-6):372-80. PubMed ID: 22269894
[TBL] [Abstract][Full Text] [Related]
8. Recent developments and advances of FGFR as a potential target in cancer.
Xue WJ; Li MT; Chen L; Sun LP; Li YY
Future Med Chem; 2018 Sep; 10(17):2109-2126. PubMed ID: 30066580
[TBL] [Abstract][Full Text] [Related]
9. De-regulated FGF receptors as therapeutic targets in cancer.
Knights V; Cook SJ
Pharmacol Ther; 2010 Jan; 125(1):105-17. PubMed ID: 19874848
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma.
Sonpavde G; Willey CD; Sudarshan S
Expert Opin Investig Drugs; 2014 Mar; 23(3):305-15. PubMed ID: 24387233
[TBL] [Abstract][Full Text] [Related]
11. Small molecule inhibition of fibroblast growth factor receptors in cancer.
Liang G; Chen G; Wei X; Zhao Y; Li X
Cytokine Growth Factor Rev; 2013 Oct; 24(5):467-75. PubMed ID: 23830577
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor receptor inhibitors.
Kumar SB; Narasu L; Gundla R; Dayam R; J A R P S
Curr Pharm Des; 2013; 19(4):687-701. PubMed ID: 23016864
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and -independent mechanisms.
Auguste P; Gürsel DB; Lemière S; Reimers D; Cuevas P; Carceller F; Di Santo JP; Bikfalvi A
Cancer Res; 2001 Feb; 61(4):1717-26. PubMed ID: 11245488
[TBL] [Abstract][Full Text] [Related]
14. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models.
Bello E; Colella G; Scarlato V; Oliva P; Berndt A; Valbusa G; Serra SC; D'Incalci M; Cavalletti E; Giavazzi R; Damia G; Camboni G
Cancer Res; 2011 Feb; 71(4):1396-405. PubMed ID: 21212416
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties.
Bono F; De Smet F; Herbert C; De Bock K; Georgiadou M; Fons P; Tjwa M; Alcouffe C; Ny A; Bianciotto M; Jonckx B; Murakami M; Lanahan AA; Michielsen C; Sibrac D; Dol-Gleizes F; Mazzone M; Zacchigna S; Herault JP; Fischer C; Rigon P; Ruiz de Almodovar C; Claes F; Blanc I; Poesen K; Zhang J; Segura I; Gueguen G; Bordes MF; Lambrechts D; Broussy R; van de Wouwer M; Michaux C; Shimada T; Jean I; Blacher S; Noel A; Motte P; Rom E; Rakic JM; Katsuma S; Schaeffer P; Yayon A; Van Schepdael A; Schwalbe H; Gervasio FL; Carmeliet G; Rozensky J; Dewerchin M; Simons M; Christopoulos A; Herbert JM; Carmeliet P
Cancer Cell; 2013 Apr; 23(4):477-88. PubMed ID: 23597562
[TBL] [Abstract][Full Text] [Related]
16. Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions.
Repetto M; Crimini E; Giugliano F; Morganti S; Belli C; Curigliano G
Expert Rev Clin Pharmacol; 2021 Oct; 14(10):1233-1252. PubMed ID: 34591728
[No Abstract] [Full Text] [Related]
17. Targeting fibroblast growth factor receptor pathway in breast cancer.
Criscitiello C; Esposito A; De Placido S; Curigliano G
Curr Opin Oncol; 2015 Nov; 27(6):452-6. PubMed ID: 26397764
[TBL] [Abstract][Full Text] [Related]
18. The role of fibroblast growth factors and their receptors in prostate cancer.
Kwabi-Addo B; Ozen M; Ittmann M
Endocr Relat Cancer; 2004 Dec; 11(4):709-24. PubMed ID: 15613447
[TBL] [Abstract][Full Text] [Related]
19. Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications.
Dianat-Moghadam H; Teimoori-Toolabi L
Curr Drug Targets; 2019; 20(8):852-870. PubMed ID: 30648505
[TBL] [Abstract][Full Text] [Related]
20. Blocking the FGF/FGFR system as a "two-compartment" antiangiogenic/antitumor approach in cancer therapy.
Giacomini A; Chiodelli P; Matarazzo S; Rusnati M; Presta M; Ronca R
Pharmacol Res; 2016 May; 107():172-185. PubMed ID: 27013279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
